Refer A Patient

Request An Appointment

Pulmonology

CINQAIR

CINQAIR (reslizumab) is a treatment for severe, uncontrolled eosinophilic asthma.
Infusion or injection therapy referral
What it treats Severe, poorly controlled asthma
Prescribed by Pulmonologists
How it’s administered Intravenous (IV) infusion
Frequency Every four weeks
Length of treatment 20 to 50 minutes, plus an observation period of 30 minutes

About This Therapy

CINQAIR (reslizumab) is a treatment for severe, uncontrolled eosinophilic asthma, and for those whose asthma is not controlled with current asthma medicines and who have high levels of eosinophils. CINQAIR is the only anti-IL-5 with personalized weight-based dosing; weight-based dosing enables your doctor to personalize a dose to you.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.

CINQAIR REFERRAL FORM

CINQAIR REFERRAL FORM

Speak with your healthcare provider to learn if this therapy is right for you, then complete the referral form below.
REFERRAL FORM →

Ready to refer a patient for CINQAIR

Our team handles benefits verification, prior authorization, and scheduling so you can focus on care.